{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:15:45Z","timestamp":1790957745213,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To determine the effect of genetic polymorphism of drug transporters on the efficacy of treatment with <jats:italic>Rosuvastatin<\/jats:italic>, <jats:italic>Atorvastatin<\/jats:italic> and <jats:italic>Simvastatin<\/jats:italic> in patients with hyperlipidemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study consists of 180 patients, aged 40\u201375\u2009years, with hyperlipidemia. All patients were divided into two equal groups: patients with different SLCO1B1 (521CC, 521CT and 521TT) and MDR1 (3435CC, 3435TC and 3435TT) genotypes. Each group was divided into rosuvastatin-treated, atorvastatin-treated and simvastatin-treated subgroups. The lipid-lowering effect of statins was assessed by tracing changes in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The use of statins over a 4-month period led to substantial reductions in TC and LDL-C levels. The hypolipidemic effect of studied agents was seen in both groups. However, it was less pronounced in patients with 521CC genotype. No statistically significantly differences were found between carriers of 3435TT, 3435CT and 3435CC genotypes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The lipid-lowering efficacy of rosuvastatin was higher compared to other two statins. Patients with <jats:italic>SLCO1B1<\/jats:italic> 521CC genotype are more likely to encounter a decrease in the hypolipidemic effect of statins. Such a risk should be considered when treating this category of patients. MDR1 polymorphism had no significant effect on statin efficacy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-021-01586-7","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T10:03:46Z","timestamp":1636365826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia"],"prefix":"10.1186","volume":"20","author":[{"given":"Andrey","family":"Sivkov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Chernus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Gorenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Sivkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Sivkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Savina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"1586_CR1","volume-title":"Metabolism of medicinal products: the fundamentals of personalized medicine","author":"VG Kukes","year":"2008","unstructured":"Kukes VG. Metabolism of medicinal products: the fundamentals of personalized medicine. GEOTARMED: Moscow; 2008."},{"key":"1586_CR2","volume-title":"Clinical pharmacology","author":"VG Kukes","year":"2016","unstructured":"Kukes VG. Clinical pharmacology. GEOTARMED: Moscow; 2016."},{"key":"1586_CR3","first-page":"1421","volume":"20","author":"MD Smirnova","year":"2017","unstructured":"Smirnova MD, Ageev FT. Statins \u2014 old myths and new facts. RMJ. 2017;20:1421\u20138.","journal-title":"RMJ"},{"key":"1586_CR4","first-page":"68","volume":"3","author":"NA Sukhaterina","year":"2016","unstructured":"Sukhaterina NA. Dynamics of lipid spectrum and markers of inflammation in hypertensive patients with chronic obstructive pulmonary disease who receive atorvastatin. JAD. 2016;3:68\u201374.","journal-title":"JAD"},{"key":"1586_CR5","first-page":"5","volume":"1","author":"VV Kukharchuk","year":"2015","unstructured":"Kukharchuk VV, Semenova AE. Correction of hyperlipidemia: statin treatment at post-marketing. The \u0441ompliance study. JAD. 2015;1:5\u201311.","journal-title":"JAD"},{"key":"1586_CR6","first-page":"886","volume":"15","author":"SV Nedogoda","year":"2015","unstructured":"Nedogoda SV. Rosuvastatin: evidence base and significance for real clinical practice. RMJ. 2015;15:886.","journal-title":"RMJ"},{"key":"1586_CR7","first-page":"5","volume":"4","author":"MV Ezhov","year":"2017","unstructured":"Ezhov MV, Bliznyuk SA, Alekseeva IA, Vygodin VA. Prevalence of hypercholesterolemia and statins intake in the outpatient practice in the Russian Federation (ICEBERG study). JAD. 2017;4:5\u201317.","journal-title":"JAD"},{"issue":"2","key":"1586_CR8","first-page":"5","volume":"10","author":"OL Barbarash","year":"2019","unstructured":"Barbarash OL, Kashtalap VV, Shibanova IA. A patient after an episode of acute coronary syndrome. Lipid control after the acute coronary syndrome. JAD. 2019;10(2):5\u201314.","journal-title":"JAD."},{"issue":"5","key":"1586_CR9","first-page":"69","volume":"8","author":"OM Drapkina","year":"2009","unstructured":"Drapkina OM. Statins in acute coronary syndrome. Cardiovasc Ther Prev\u044e. 2009;8(5):69\u201373.","journal-title":"Cardiovasc Ther Prev\u044e"},{"issue":"2","key":"1586_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1463-1326.2008.00917.x","volume":"11","author":"R Franssen","year":"2009","unstructured":"Franssen R, Vergeer M, Stroes ES, Kastelein JJ. Combination statin\u2013fibrate therapy: safety aspects. Diabetes Obes Metab. 2009;11(2):89\u201394. https:\/\/doi.org\/10.1111\/j.1463-1326.2008.00917.x.","journal-title":"Diabetes Obes Metab"},{"issue":"3 Suppl","key":"1586_CR11","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","volume":"8","author":"H Bays","year":"2014","unstructured":"Bays H, Cohen DE, Chalasani N, Harrison SA. The National Lipid Association\u2019s statin safety task force. An assessment by the statin liver safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S47\u201357. https:\/\/doi.org\/10.1016\/j.jacl.2014.02.011.","journal-title":"J Clin Lipidol."},{"key":"1586_CR12","doi-asserted-by":"publisher","unstructured":"Goroshko OA, Krasnykh LM, Kukes VG, Zozina VI. Evaluation of coenzyme Q10 redox status as a biomarker of oxidativestress, Bull Scientif Centre Exp Eval Medicin Prod. 2019;9(3):146\u201352. https:\/\/doi.org\/10.30895\/1991-2919-2019-9-3-146-152.","DOI":"10.30895\/1991-2919-2019-9-3-146-152"},{"issue":"1","key":"1586_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","volume":"127","author":"BA Parker","year":"2013","unstructured":"Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96\u2013103. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.136101.","journal-title":"Circulation."},{"issue":"10","key":"1586_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.26442\/2075-1753_2018.10.20-28","volume":"20","author":"MV Leonova","year":"2018","unstructured":"Leonova MV, Gaysenok OV, Leonov AS. Statins pharmacogenetics: metabolizing enzymes and transporters polymorphisms role. Consilium Medicum. 2018;20(10):20\u20138. https:\/\/doi.org\/10.26442\/2075-1753_2018.10.20-28.","journal-title":"Consilium Medicum"},{"issue":"8","key":"1586_CR15","doi-asserted-by":"publisher","first-page":"CR512","DOI":"10.12659\/msm.883272","volume":"18","author":"H Buzkov\u00e1","year":"2012","unstructured":"Buzkov\u00e1 H, Pechandov\u00e1 K, Danzig V, Vareka T, Perlik F, Zak A, et al. Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. Med Sci Monit. 2012;18(8):CR512\u20137. https:\/\/doi.org\/10.12659\/msm.883272.","journal-title":"Med Sci Monit"},{"issue":"2","key":"1586_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jacl.2011.01.001","volume":"5","author":"MR Hoenig","year":"2011","unstructured":"Hoenig MR, Walker PJ, Gurnsey C, Beadle K, Johnson L. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J Clin Lipidol. 2011;5(2):91\u20136. https:\/\/doi.org\/10.1016\/j.jacl.2011.01.001.","journal-title":"J Clin Lipidol"},{"issue":"Suppl 3","key":"1586_CR17","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1016\/j.ihj.2018.07.009","volume":"70","author":"N Ramakumari","year":"2018","unstructured":"Ramakumari N, Indumathi B, Katkam SK, Kutala VK. Impact of pharmacogenetics on statin-induced myopathy in south-Indian subjects. Indian Heart J. 2018;70(Suppl 3):S120\u20135. https:\/\/doi.org\/10.1016\/j.ihj.2018.07.009.","journal-title":"Indian Heart J"},{"issue":"2","key":"1586_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4172\/2153-0645.1000128","volume":"5","author":"JA Talameh","year":"2014","unstructured":"Talameh JA, Kitzmiller JP. Pharmacogenetics of statin-induced myopathy: a focused review of the clinical translation of pharmacokineticgenetic variants. J Pharmacogenomics Pharmacoproteomics. 2014;5(2):128. https:\/\/doi.org\/10.4172\/2153-0645.1000128.","journal-title":"J Pharmacogenomics Pharmacoproteomics"},{"issue":"1","key":"1586_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/pr.110.002857","volume":"63","author":"M Niemi","year":"2011","unstructured":"Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63(1):157\u201381. https:\/\/doi.org\/10.1124\/pr.110.002857.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1586_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.30895\/2312-7821-2020-8-1-43-51","volume":"8","author":"K RYe","year":"2020","unstructured":"RYe K, Checha OA, Mazerkina IA, Muslimova OV, EYu D, Alexandrova TV, et al. Pharmacogenetic approaches to enhancing efficacy and safety of statins as illustrated by the example of atorvastatin. Safety Risk Pharmacother. 2020;8(1):43\u201351. https:\/\/doi.org\/10.30895\/2312-7821-2020-8-1-43-51.","journal-title":"Safety Risk Pharmacother"},{"issue":"4","key":"1586_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.14300\/mnnc.2019.14160","volume":"14","author":"NA Rumyantsev","year":"2019","unstructured":"Rumyantsev NA, Kukes VG, Grapov DO. Experience in the implementation of pharmacogenetic testing in clinical practice at the administration of statin group drugs. Analysis of longterm therapy results. Med News North Caucasus. 2019;14(4):646\u20139. https:\/\/doi.org\/10.14300\/mnnc.2019.14160.","journal-title":"Med News North Caucasus"},{"key":"1586_CR22","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2147\/DDDT.S131487","volume":"11","author":"HI Woo","year":"2017","unstructured":"Woo HI, Kim SR, Huh W, Ko JW, Lee SY. Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. Drug Des Devel Ther. 2017;11:1135\u201346. https:\/\/doi.org\/10.2147\/DDDT.S131487.","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"1586_CR23","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.1007\/s11033-014-3334-z","volume":"41","author":"E Giannakopoulou","year":"2014","unstructured":"Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis AD, Elisaf M, et al. No impact of SLCO1B1 521T>C, 388A>G and 411G>a polymorphisms on response to statin therapy in the Greek population. Mol Biol Rep. 2014;41(7):4631\u20138. https:\/\/doi.org\/10.1007\/s11033-014-3334-z.","journal-title":"Mol Biol Rep"},{"key":"1586_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/PGPM.S86013","volume":"9","author":"JP Kitzmiller","year":"2016","unstructured":"Kitzmiller JP, Mikulik EB, Dauki AM, Murkherjee C, Luzum JA. Pharmacogenomics of statins: understanding susceptibility to adverse effects. CPPM. 2016;9:97\u2013106. https:\/\/doi.org\/10.2147\/PGPM.S86013.","journal-title":"CPPM."},{"issue":"1","key":"1586_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12944-015-0114-2","volume":"14","author":"J Su","year":"2015","unstructured":"Su J, Xu H, Yang J, Yu Q, Yang S, Zhang J, et al. ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis. Lipids Health Dis. 2015;14(1):122. https:\/\/doi.org\/10.1186\/s12944-015-0114-2.","journal-title":"Lipids Health Dis"},{"issue":"5","key":"1586_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2133\/dmpk.19.375","volume":"19","author":"R Tachibana-Iimori","year":"2004","unstructured":"Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet. 2004;19(5):375\u201380. https:\/\/doi.org\/10.2133\/dmpk.19.375.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"1586_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.20996\/1819-6446-2008-4-2-47-50","volume":"2","author":"AV Semenov","year":"2008","unstructured":"Semenov AV, Sychev DA, Kukes VG. The effect of SLCO1B1 and MDR1 polymorphism on the pharmacokinetics and pharmacodynamics of atorvastatin in patients with primary hypercholesterolemia: a pilot pharmacogenetic study. Ration Pharmacother Cardiol. 2008;2(2):47\u201350. https:\/\/doi.org\/10.20996\/1819-6446-2008-4-2-47-50.","journal-title":"Ration Pharmacother Cardiol"},{"issue":"3","key":"1586_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3343\/alm.2015.35.3.329","volume":"35","author":"Y Dou","year":"2015","unstructured":"Dou Y, Zhu X, Wang Q, Tian X, Cheng J, Zhang E. Meta-analysis of the SLCO1B1 c.521T>C variant reveals slight influence on the lipid-lowering efficacy of statins. Ann Lab Med. 2015;35(3):329\u201335. https:\/\/doi.org\/10.3343\/alm.2015.35.3.329.","journal-title":"Ann Lab Med"},{"issue":"8","key":"1586_CR29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.5551\/jat.26856","volume":"22","author":"R Dai","year":"2015","unstructured":"Dai R, Feng J, Wang Y, Yang Y, Deng C, Tang X, et al. Association between SLCO1B1 521T>C and 388A>G polymorphisms and statin effectiveness: a meta-analysis. J Atheroscler Thromb. 2015;22(8):796\u2013815. https:\/\/doi.org\/10.5551\/jat.26856.","journal-title":"J Atheroscler Thromb"},{"issue":"37","key":"1586_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001268","volume":"94","author":"Q Hou","year":"2015","unstructured":"Hou Q, Li S, Li L, Li Y, Sun X, Tian H. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case-control studies. Medicine. 2015;94(37):e1268. https:\/\/doi.org\/10.1097\/MD.0000000000001268.","journal-title":"Medicine."},{"issue":"1","key":"1586_CR31","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1186\/s40064-016-2912-z","volume":"5","author":"J Jiang","year":"2016","unstructured":"Jiang J, Tang Q, Feng J, Dai R, Wang Y, Yang Y, et al. Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. SpringerPlus. 2016;5(1):1368. https:\/\/doi.org\/10.1186\/s40064-016-2912-z.","journal-title":"SpringerPlus."},{"issue":"11","key":"1586_CR32","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/gim.2014.41","volume":"16","author":"WJ Canestaro","year":"2014","unstructured":"Canestaro WJ, Austin MA, Thummel KE. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet Med. 2014;16(11):810\u20139. https:\/\/doi.org\/10.1038\/gim.2014.41.","journal-title":"Genet Med"},{"issue":"4","key":"1586_CR33","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00228-020-03029-1","volume":"77","author":"Q Xiang","year":"2021","unstructured":"Xiang Q, Zhang XD, Mu GY, Wang Z, Liu ZY, Xie QF, et al. Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis. Eur J Clin Pharmacol. 2021;77(4):569\u201381. https:\/\/doi.org\/10.1007\/s00228-020-03029-1.","journal-title":"Eur J Clin Pharmacol"},{"key":"1586_CR34","unstructured":"US Food and Drug Administration FDA Drug Safety Communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. 2010. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm204882.htm. ."},{"issue":"4","key":"1586_CR35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/clpt.2014.125","volume":"96","author":"LB Ramsey","year":"2014","unstructured":"Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. CPT. 2014;96(4):423\u20138. https:\/\/doi.org\/10.1038\/clpt.2014.125.","journal-title":"CPT."},{"issue":"5","key":"1586_CR36","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","volume":"78","author":"M Fiegenbaum","year":"2005","unstructured":"Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. CPT. 2005;78(5):551\u20138. https:\/\/doi.org\/10.1016\/j.clpt.2005.08.003.","journal-title":"CPT."},{"key":"1586_CR37","unstructured":"Mal GS, Kuvshinova YuA. The use of lipid-lowering agents with the help of genetic markers in patients with coronary artery disease. LJournal.ru. 2013;3."},{"issue":"3","key":"1586_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.33380\/2305-2066-2020-9-3-28-35","volume":"9","author":"TA Bitkina","year":"2020","unstructured":"Bitkina TA, Basevich AV, Rodin VM. Critical points for the production of polymeric microspheres used in X-Ray surgery. Drug Dev Registr. 2020;9(3):28\u201335. https:\/\/doi.org\/10.33380\/2305-2066-2020-9-3-28-35.","journal-title":"Drug Dev Registr"},{"issue":"3","key":"1586_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.33380\/2305-2066-2020-9-3-21-26","volume":"9","author":"B Lugen","year":"2020","unstructured":"Lugen B, Dmitrieva MV, Orlova OL, Krasnyuk II, Krasnyuk II Jr, Bokov DO, et al. Development of a liposomal dosage form based on hydrophobic derivative of indolocarbazole. Drug Dev Registr. 2020;9(3):21\u20136. https:\/\/doi.org\/10.33380\/2305-2066-2020-9-3-21-26.","journal-title":"Drug Dev Registr"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-021-01586-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T10:07:47Z","timestamp":1636366067000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01586-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1586"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01586-7","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"assertion":[{"value":"30 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the work is written with due consideration of ethical standards. The study was conducted in accordance with the ethical principles approved by the Human Experiments Ethics Committee of I.M. Sechenov First Moscow State Medical University (Sechenov University) (Protocol No 12 of 12.06.2020). All the participants have given their written informed consent to the participation in the research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the participants have given their consent to the publication of the research results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}